aspirin has been researched along with dihydropyridines in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Angelberger, P; Gerakakis, A; Keiler, A; Lupattelli, G; Pirich, C; Sinzinger, H; Virgolini, I | 1 |
| Fitscha, P; Keiler, A; O'Grady, J; Rauscha, F; Sinzinger, H | 1 |
| Fetkovska, N; Jakubovska, Z; Oravcova, J; Tison, P; Ulicna, L | 2 |
| Kakishita, M; Nakamura, K; Ohe, T; Yamanari, H | 1 |
| Durstberger, M; Eichelberger, B; Gremmel, T; Koppensteiner, R; Panzer, S | 1 |
2 trial(s) available for aspirin and dihydropyridines
| Article | Year |
|---|---|
Effects of dihydropyridines and their combination with aspirin on blood pressure and circadian platelet activity in patients with essential hypertension.
Topics: Adult; Aspirin; Blood Platelets; Blood Pressure; Circadian Rhythm; Dihydropyridines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Isradipine; Male; Middle Aged; Nitrendipine | 1994 |
Treatment of hypertension with dihydropyridine calcium antagonists and aspirin.
Topics: Adult; Aspirin; Blood Platelets; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm; Dihydropyridines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Isradipine; Male; Middle Aged; Nitrendipine | 1994 |
4 other study(ies) available for aspirin and dihydropyridines
| Article | Year |
|---|---|
Concomitant aspirin treatment abolishes the antiatherosclerotic effects of the calcium channel blocker isradipine mediated by PGI2.
Topics: Animals; Aorta, Abdominal; Arteriosclerosis; Aspirin; Calcium Channel Blockers; Cholesterol; Dihydropyridines; Epoprostenol; Humans; Hypercholesterolemia; Isradipine; Kinetics; Lipid Metabolism; Lipoproteins, LDL; Male; Rabbits | 1992 |
The diminished extracellular matrix production induced by isradipine, a calcium channel blocker, is completely abolished by cyclooxygenase inhibition.
Topics: Animals; Arteriosclerosis; Aspirin; Calcium Channel Blockers; Collagen; Cyclooxygenase Inhibitors; Dihydropyridines; Drug Interactions; Epoprostenol; Extracellular Matrix; Glycosaminoglycans; Isradipine; Male; Rabbits | 1992 |
Effects of cyclooxygenase inhibition on endothelial function in hypertensive patients treated with angiotensin-converting enzyme inhibitors.
Topics: Administration, Sublingual; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Case-Control Studies; Cyclooxygenase Inhibitors; Dihydropyridines; Enalapril; Endothelium, Vascular; Female; Humans; Hypertension; Male; Metoprolol; Middle Aged; Nitrobenzenes; Nitroglycerin; Piperazines; Platelet Aggregation Inhibitors; Regional Blood Flow; Vasodilator Agents | 2004 |
Calcium-Channel Blockers Attenuate the Antiplatelet Effect of Clopidogrel.
Topics: Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Calcium Channel Blockers; Clopidogrel; Dihydropyridines; Drug Interactions; Female; Flow Cytometry; Humans; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Ticlopidine | 2015 |